Filtered By:
Cancer: Leukemia
Therapy: Chemotherapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 3841 results found since Jan 2013.
Immune checkpoint molecule DNAM-1/CD112 axis is a novel target for NK-cell therapy in acute myeloid leukemia
In conclusion, the modification of the DNAM-1/CD112 axis in NK cells may be an effective novel immunotherapy for AML. Furthermore, these results suggest the potential of the expression levels of these molecules as prognostic markers in AML.PMID:37731380 | DOI:10.3324/haematol.2023.282915
Source: Haematologica - September 21, 2023 Category: Hematology Authors: Yuta Kaito Emi Sugimoto Fumi Nakamura Yutaka Tsukune Makoto Sasaki Shunsuke Yui Hiroki Yamaguchi Susumu Goyama Yasuhito Nannya Kinuko Mitani Hideto Tamura Yoichi Imai Source Type: research
Early T-Cell Precursor Leukemia: A High-Risk Subtype of Acute Lymphoblastic Leukemia, Single Center Experience in Jordan
CONCLUSION: ETP-ALL/LBL represents a high-risk disease subtype of adult ALL. Novel treatment strategies are needed to improve treatment outcomes in this patient's population.PMID:37730482 | DOI:10.1016/j.clml.2023.08.007
Source: Clinical Lymphoma and Myeloma - September 20, 2023 Category: Cancer & Oncology Authors: Khalid Halahleh Isra Muradi Mohammad Zakaria Khalil Lina Halahleh Maher Sughayer Nazmi Kamal Iyad Sultan Kamal Alrabi Source Type: research
Impact of previous anthracycline therapy in patients with acute myeloid leukemia receiving venetoclax
In this study, prior chemotherapy/allo-SCT and cytogenetic risk were associated with VEN treatment outcomes.PMID:37728705 | DOI:10.1007/s12185-023-03664-1
Source: International Journal of Hematology - September 20, 2023 Category: Hematology Authors: Ryujiro Hara Shinichiro Machida Norisato Hashimoto Daisuke Ogiya Hidetsugu Kawai Shohei Kawakami Sawako Shiraiwa Makoto Onizuka Yoshiaki Ogawa Hiroshi Kawada Kiyoshi Ando Source Type: research
Harnessing autologous immune effector mechanisms in acute myeloid leukemia: 2023 update of trials and tribulations
Leuk Res. 2023 Sep 14;134:107388. doi: 10.1016/j.leukres.2023.107388. Online ahead of print.ABSTRACTNumerous recent advances have been made in therapeutic approaches toward acute myeloid leukemia (AML). Since 2017, we have seen eleven novel Food & Drug Administration (FDA)-approved medications for AML, all of which extend beyond the classical cytarabine-based cytostatic chemotherapy. In the recent two decades, the role of immune surveillance in AML has been intensively investigated. The power of one's own innate and adaptive immunity has been harnessed pharmacologically toward the goal of clearance of AML cells. Specif...
Source: Cell Research - September 20, 2023 Category: Cytology Authors: Shyam A Patel Elisa Bello Andrew Wilks Jonathan M Gerber Narayanan Sadagopan Jan Cerny Source Type: research
Novel bacterial topoisomerase inhibitors: unique targeting activities of amide enzyme-binding motifs for tricyclic analogs
Antimicrob Agents Chemother. 2023 Sep 19:e0048223. doi: 10.1128/aac.00482-23. Online ahead of print.ABSTRACTAntimicrobial resistance has made a sizeable impact on public health and continues to threaten the effectiveness of antibacterial therapies. Novel bacterial topoisomerase inhibitors (NBTIs) are a promising class of antibacterial agents with a unique binding mode and distinct pharmacology that enables them to evade existing resistance mechanisms. The clinical development of NBTIs has been plagued by several issues, including cardiovascular safety. Herein, we report a sub-series of tricyclic NBTIs bearing an amide link...
Source: Antimicrobial Agents and Chemotherapy - September 19, 2023 Category: Microbiology Authors: Chelsea A Mann Jessika J Carvajal Moreno Yanran Lu Sheri Dellos-Nolan Daniel J Wozniak Jack C Yalowich Mark J Mitton-Fry Source Type: research
Case Report: Case Series of Kocuria palustris Bacteremia among Immunocompromised Patients
We present three cases of bacteremia in immunocompromised patients admitted to our hospital; one patient was receiving chemotherapy for gall bladder carcinoma, the second was on maintenance hemodialysis for chronic kidney disease, and the third was receiving chemotherapy for acute myeloid leukemia. All three patients presented with a fever in the setting of neutropenia during the course of treatment with chemotherapy (in Cases 1 and 3) or hemodialysis (in Case 2). The blood culture samples of all the patients had pure isolates of Kocuria species K. palustris, which was identified by matrix assisted laser desorption ionisat...
Source: The American Journal of Tropical Medicine and Hygiene - September 18, 2023 Category: Tropical Medicine Authors: Gerlin Varghese Ashima Jamwal Deepika Sarawat Chinmoy Sahu Sangram Singh Patel Nidhi Tejan Source Type: research
High-throughput screening as a drug repurposing strategy for poor outcome subgroups of pediatric B-cell precursor Acute Lymphoblastic Leukemia
Biochem Pharmacol. 2023 Sep 15:115809. doi: 10.1016/j.bcp.2023.115809. Online ahead of print.ABSTRACTAlthough a great cure rate has been achieved for pediatric BCP-ALL, approximately 15% of patients do not respond to conventional chemotherapy and experience disease relapse. A major effort to improve the cure rates by treatment intensification would result in an undesirable increase in treatment-related toxicity and mortality, raising the need to identify novel therapeutic approaches. High-throughput (HTP) drug screening enables the profiling of patients' responses in vitro and allows the repurposing of compounds currently ...
Source: Biochemical Pharmacology - September 17, 2023 Category: Drugs & Pharmacology Authors: Athanasios Oikonomou Luigia Valsecchi Manuel Quadri Titus Watrin Katerina Scharov Simona Procopio Jia-Wey Tu Melina Vogt Angela Maria Savino Daniela Silvestri Maria Grazia Valsecchi Andrea Biondi Arndt Borkhardt Sanil Bhatia Giovanni Cazzaniga Grazia Fazi Source Type: research
Genes, Vol. 14, Pages 1807: Aldehyde Dehydrogenase Genes as Prospective Actionable Targets in Acute Myeloid Leukemia
In conclusion, we identify ALDH1A1 and ALDH2 as prospective actionable targets for the treatment of AML in high-risk patients. Substances that inhibit both enzymatic activities constitute potentially effective pharmaceutics.
Source: Genes - September 16, 2023 Category: Genetics & Stem Cells Authors: Garrett M. Dancik Lokman Varisli Veysel Tolan Spiros Vlahopoulos Tags: Article Source Type: research
A Patient Presenting for Dental Extraction After Completion of Chemotherapy
Dent Clin North Am. 2023 Oct;67(4):667-670. doi: 10.1016/j.cden.2023.05.020. Epub 2023 Jun 18.ABSTRACTAcute myeloid leukemia (AML) presents several oral manifestations, including gingival hyperplasia, pale mucosa, poor wound healing, petechiae, ecchymoses, candidiasis, recurrent herpes infection, and ulcerations in the oral mucosa. Chemotherapy is the first-line treatment of AML. Common dental complications of chemotherapy include mucositis, infections secondary to profound bone marrow aplasia, and gingival bleeding. When treating patients with AML, preparing a comprehensive treatment plan is essential to help minimize the...
Source: Herpes - September 15, 2023 Category: Infectious Diseases Authors: Walter W Hong Irene H Kim Brad M Hong Sophia Oak Mel Mupparapu Source Type: research
Prognostic value of European Leukemia Net 2022 criteria and genomic clusters using machine learning in older adults with acute myeloid leukemia
This study aimed to validate the new European Leukemia Net (ELN) 2022 criteria for genetic risk stratification in older adults with acute myeloid leukemia (AML) and to determine the most likely set of clusters of similar cytogenetic and mutation properties correlated with survival outcomes in three treatment groups: intensive chemotherapy (IC), hypomethylating agents (HMAs) alone, and HMAs plus venetoclax (HMA/VEN). The study included 279 patients (≥60 years) who received IC (n=131), HMA (n=76), and HMA/VEN (n=72) between July 2017 and October 2021. No significant differences were observed in survival among the groups ac...
Source: Haematologica - September 14, 2023 Category: Hematology Authors: Silvia Park Tong Yoon Kim Byung-Sik Cho Daehun Kwag Jong-Mi Lee MyungShin Kim Yonggoo Kim Jamin Koo Anjali Raman Tae Kon Kim Hee-Je Kim Source Type: research
